HYFT MindWalk Holdings Corp.

$HYFT I believe we’re entering NEWS SEASON for MindWalk. There are a LOT of potential catalysts sitting on the table right now: 1. Neutralization data The science needs to keep validating what MindWalk has built. Strong results could materially advance the internal pipeline. 2. Cayman Islands financing Management said the legal/tax work was ~90–95% complete. Then MindWalk adds Kim Remizowski — 35+ years in Cayman banking, private equity, funds and investment structures — to the board. Interesting timing. 3. Bigger Big Pharma contracts MindWalk is already talking about contracted, recurring ReefIQ deployments. Now give us names, dollars and evidence that ReefIQ can be duplicated across Big Pharma. 4. AMD + Vultr AMD isn’t just a logo on a slide. MindWalk has been showcased at AMD events. AMD published a dedicated MindWalk case study. AMD + Vultr infrastructure is powering its OpenFold3 deployment. And management specifically told us there is “MORE TO COME” regarding this relationship. 5. ReefIQ commercial numbers How many deployments? ARR per customer? Contract length? Expansion potential? Once investors can put real numbers behind recurring ReefIQ revenue, they can start putting a real valuation on the platform. 6. Internal pipeline financing/partnerships Completing the Cayman structure is one thing. Putting outside capital into individual MindWalk drug programs is another. If MindWalk can advance assets with outside capital while retaining meaningful economics, that’s a potentially important part of the model. 7. $30M Sanabil facility Confirmation that the facility is fully operational would give MindWalk another source of capital as these programs and ReefIQ scale. 8. WILD CARD — another board addition They just added serious Cayman financial expertise. What happens if the next addition brings Big Pharma or major AI/infrastructure experience? Any ONE of these moves the story forward. Start stacking several together and $HYFT begins looking like a very different company than the one the market is valuing today. The pieces are on the board. Now let’s see the news.

$HYFT Honestly, it’s hard to find another biotech company besides $HYFT with a low-CapEx, high-ROI business model. Most biotech companies make money through outsourcing or successful drug development, but those models are far less stable and carry much higher risk. In theory, $HYFT has one of the strongest business models in biotech. Management aside, of course lol.

$HYFT Jennifer Bath, enough is enough. While shareholders wait for neutralization results, Cayman financing, and major pharma contracts, we get another technical announcement, more senior hires, and another board member. Six years of spending, generous executive compensation, and stock awards potentially diluting shareholders. Where is the meaningful revenue? Listen, it's excellent that the software is performing as shareholders expected it would all along. We believe in the technology. What we question is management's ability to monetize it. How can shareholders trust a board that continues approving compensation without demanding measurable financial results? Shareholders need execution and accountability, not more promises, presentations, or technical advancements with no revenue attached. Jennifer, it's time to execute!

$HYFT As I sit here thinking about everything that has happened over the last two years, I see a slow-moving tugboat. Frustratingly slow, at times barely moving, but moving nonetheless. I've been critical of this management team for many, many reasons over the last six years. And I'm not suddenly forgetting any of that. But sometimes you have to step back and look at the bigger picture. We're talking about a company with roughly a $50 million market cap and $10 million in cash that has a TRILLION-DOLLAR company, AMD, paying attention to its technology. The Cayman Islands funding discussions started 9+ months ago. We were promised a major update in two weeks, and then... radio silence. That kind of communication is frustrating and, in my opinion, reflects a management team that may lack real-world biotech financing experience. But the story didn't die. Now we have a $30 MILLION credit facility from Sanabil, a Cayman-based financing structure, and a new board member with substantial experience in Cayman Islands financial services. Is everything legitimate? Based on the pieces of evidence we can see, I have reasons to believe there is substance here. But financing access is not proof of commercial success, and AMD's attention is not the same as a major pharma contract. Are we being lied to? I have a hard time believing that is the most likely explanation. Are we watching an inexperienced management team learn as they go, making mistakes, moving slowly, and communicating poorly while trying to build something far bigger than the company they started with? That seems far more plausible to me. I've criticized this team for six years. I'll continue to demand accountability. But I'm also willing to acknowledge when the pieces start moving in the right direction. The tugboat is still slow. But it's alive. And I'm watching to see where it goes next.

$HYFT moin , Der chart steht auf grün ,kaufen kaufen kaufen ,heimlicher Tipp der noch Erst wach werden muss.

$HYFT F N hell Dummy F CEO & reason for us investors being stuck with this lump of C R A P SP. Comments about weak low SP & only re - releases EDU updates & info that's already in MKT. Thus the reason SP remains below 5 with no knew Institutional Buyers that wont & often can't position under 5 SP - minimal Volume. If in the invent SP does go 5 it might be an extremely hard sell but at least investors wont be SUCKING AIR. Bath please step aside & find a Real CEO its the right thing to do PERIOD

$HYFT Assume for a min ONE of & or out of 19 of the Top 20 Big Pharma CO's HYFT is already doing buisness with decides to take a postion in HYFT open MKT or NONE open MKT... that would make a great Filing! $AMD already has an equity portfolio worth 1.3 Billion not a Pharma so for example $GILD has an equity portfolio worth 1.65 Billion. HYFT MKT CAP 68 Million & Trading dirt Cheap. Post a Price target thats not BS. HYFT at 20 per share would still only have a MKT CAP of 940 Million = Drop in a Bucket to many of COs HYFT is already doing biz with.

$HYFT It’s time for desperate pumpers to start quoting snd reposting their own pumps!! Jfc. We are just an ATM for Bath.

$HYFT "The chart is flashing green—buy, buy, buy—a sleeper pick that’s just waiting to wake up." All us long suffering longs can hardly wait!

$HYFT Mindwalk (nasdaq: hyft): enterprise ai has found its ontology layer. biology needs one grounded in biological function

$HYFT Not enough confirmation lately. Even though the price is consolidating at new supports, the price action hasn’t shown any significant growth.